{
  "id": 7727,
  "origin_website": "Bio",
  "title": "Fluorescence Screens for Identifying Central Nervous System‚ÄìActing Drug‚ÄìBiosensor Pairs for Subcellular and Supracellular Pharmacokinetics",
  "procedures": [
    "Expression of biosensor proteinsChemical transformation of plasmid into BL21(DE3) chemically competent cellsDetermine biosensor plasmid to express. Coding regions of each candidate biosensor are given in the iSnFRbase database (a repository for tracking biosensor mutagenesis and drug affinities), which will be deposited on GitHub. Figures 4, 5, and 6 give the iSnFRbase identifiers under nicknames.Add 300 ng of biosensor of chosen plasmid DNA to 100 ¬µL of BL21(DE3) chemically competent cells on ice for 10‚Äì30 min.After incubation, heat-shock the sample on a 42 ¬∞C heat block for 30 s and place back on ice for 2 min.Add 700 ¬µL of SOC media to the sample, resuspend solution with a pipette, and place the sample in a 37 ¬∞C shaker for 1 h at 225 rpm.Spin the sample in a microcentrifuge for 2 min.Remove 500 ¬µL of supernatant and resuspend the pellet in the remaining supernatant.Add 60 ¬µL of resuspended sample to an LB agar plate containing 100 mg/mL ampicillin (or appropriate antibiotic) and spread media on plate using 5‚Äì10 sterile glass beads.Keep the plate in a 37 ¬∞C incubator for 16‚Äì20 h.Note: The volume of BL21(DE3) chemo-competent cells plated can be reduced if colony density on LB agar plates is too high after 37 ¬∞C incubation. InoculationPick a single colony from the previously grown LB agar plate and add it to a mixture of 192 mL autoclaved LB (made from Difco LB media) and auto-induction additives (4 mL of 50√ó M, 4 mL of 50√ó 5052, 200 ¬µL of ampicillin 1,000√ó stock, and 40 ¬µL of 1 M MgSO4) (Studier, 2005).Swirl the flask and place in a 30 ¬∞C shaking incubator for 24‚Äì30 h at 240 rpm.Transfer the culture into four 50 mL Falcon tubes and centrifuge for 15 min at 5,300 √ó g and 4 ¬∞C.",
    "Decant samples, gently wash each pellet once with 5 mL of 1√ó PBS, pH 7.0, and store the tubes at -80 ¬∞C for later purification (storage at temperatures above -80 ¬∞C may result in degraded, non-functional protein).Note: Initial auto-induction volume can be increased or decreased depending on protein yield as calculated in step A6h. Preparation for purificationThaw 50 mL Falcon tubes containing pelleted biosensor culture on ice.Add 5 mL 1√ó PBS, pH 7.0, to each tube and completely resuspend pellet while on ice.Pool resuspensions into a single 50 mL Falcon tube and place it on ice.Sonicate the resuspended biosensor at 13% amplitude, 0.7 s time-on, and 0.2 s time-off for 30 s. Repeat sonication three to six times, with 3 min between each sonication to allow for cooling.CRITICAL STEP¬†Effective sonication is required for maximum protein yield. Increase the number of sonication cycles or sonication amplitude if the yield calculated in Step A6h is low. Centrifuge the sample for 15 min at 5,300 √ó g and 4 ¬∞C.Collect the supernatant while being careful to avoid collecting any pellet and transfer it to a new 50 mL Falcon tube. CRITICAL STEP¬†If some pellet is gathered with the supernatant, this will markedly lengthen the filtration step in Step A3h.Note: An additional 15 min centrifugation and transfer to a new 50 mL Falcon tube may facilitate filtration in later steps. Attach a 0.2 ¬µm filter to a 10 mL syringe and place over a new 50 mL Falcon tube.Remove syringe plunger and add the previously collected supernatant to the 10 mL syringe, replace syringe plunger, and depress plunger to filter.Note: Multiple 0.2 ¬µm filters may be required to filter one sample; these may be replaced on the 10 mL syringe. Ensure that filtered and unfiltered supernatant are not mixed during 0.",
    "2 ¬µm filter replacement.¬†CRITICAL STEP¬†Unfiltered supernatant can result in bacterial growth in fast protein liquid chromatography (FPLC) systems. Repeat filtration step with remaining supernatant until the entire sample is filtered.Note: Multiple 0.2 ¬µm filtrations may be performed in parallel. Pool 0.2 ¬µm filtered supernatant into one 50 mL Falcon tube (as needed). FPLC purificationEquilibrate Ni-NTA column according to manufacturer‚Äôs guidelines.Note: For general FPLC setup, see Figure 1. Equilibrate appropriate FPLC lines with Buffer A and Buffer B.Run an appropriate protein purification method (example program: seven column volume (CV) applications of 100% Buffer A, sample application 10‚Äì30 mL, seven CV washouts of unbound protein with 100% Buffer A, 0%‚Äì100% Buffer B gradient elution over 10 CV, five CV applications of 100% Buffer B, and collect 4 mL fractions starting at Buffer B gradient elution step).When prompted to load the sample, load the filtered biosensor solution using either the 1) sample loop or 2) sample valve as appropriate for the supernatant volume and FPLC model.When purification program is complete, remove fractions from the FPLC carousel and store at 4 ¬∞C.CRITICAL STEP¬†To ensure minimal cross-contamination of biosensors, column stripping and regeneration is recommended when purifying multiple constructs in succession. Run an appropriate program to strip the column using 50 mM EDTA and 0.05% SDS, followed by 0.5 M NaOH (example program: five CV applications of EDTA 0.05% SDS, two CV applications of H2O, and five CV applications of 0.5 M NaOH).Note: If changing bottles between programs, wash the lines with water before equilibrating with the new solution.¬†CRITICAL STEP¬†Direct mixing of buffers without a water wash may result in precipitation of nickel in FPLC lines, affecting FPLC function.¬†TROUBLESHOOTING¬†If precipitation is seen, wash lines extensively with water to remove precipitate.",
    "Run an appropriate program to regenerate the column using 0.2 M NiSO4, followed by storage in 20% EtOH (example program: five CV applications of nickel sulfate, three CV applications of H2O, and five CV applications of 20% EtOH).Ensure that all lines are stored in 20% EtOH to reduce bacterial growth.imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g001.jpgFigure 1. Fast protein liquid chromatography (FPLC) setup. The FPLC machine used for protein purification is shown with lines, waste, and fraction collector.Protein gel electrophoresisAdd 20 ¬µL of 2-mercaptoethanol (Œ≤-ME) and 180 ¬µL of 4√ó Laemmli sample buffer to a 1.5 mL microcentrifuge tube and mix by a brief microcentrifuge spin.Identify protein fractions to sample from the FPLC purification.Note: A general rule is to sample the range that covers the fractions of detectable protein elution, with a buffer of several fractions on either end of this range. If needed, sample every third or fourth fraction. Add 20 ¬µL of each chosen protein fraction from purification to 1.5 mL microcentrifuge tubes.Add 10 ¬µL of the mixture of Œ≤-ME and Laemmli sample buffer made in StepA5a a to each protein fraction sample.Mix tube contents by a brief microcentrifuge spin.Place samples in a 95 ¬∞C heat block for 10 min.Add 30 ¬µL 10-well Mini-PROTEAN TGXTM precast protein gel to a gel box and fill the box with Tris-glycine buffer (diluted from 10√ó concentrate).After 95 ¬∞C incubation is completed, briefly spin down 1.5 mL microcentrifuge tubes and fill lanes 2‚Äì10 of the gel with 20 ŒºL of the FPLC-purified fraction solution. Add 1.5 ¬µL of Bio-Rad Precision Plus protein dual color standards to lane 1.Run the gel for 1 h and 10 min at 110 V (or for the time recommended by manufacturer).",
    "Remove the gel from its casting by crimping, place in a coverable container, add Coomassie stain, and place on a rotary shaker on a light setting overnight.The next morning, decant the Coomassie stain (which can be saved for future gels) and rinse the gel with water.Incubate the gel with water on the rotary shaker until it becomes clear (the protein bands should be blue).Note: To hasten the destaining process, replace the water every 10‚Äì15 min. Once the gel is clear, examine the protein bands in lanes 2‚Äì10 and compare these to the protein ladder (lane 1) to determine whether the protein bands match the molecular weight of the desired protein.Note: Bands of lower or higher molecular weight may be visible along with the desired protein and indicate unwanted proteins.¬†CRITICAL STEP¬†Care should be taken to concentrate biosensor protein fractions with minimal contamination from these other proteins. If desired, size-exclusion chromatography can be performed to further increase protein purity. Concentration of purified proteinTransfer 8 mL of 1√ó PBS, pH 7.0, to a 50 mL centrifugal filter (30 kDa cutoff).Centrifuge the tube for 9 min at 3,400 √ó g and 4 ¬∞C to wash the filter.Add 11 mL of the chosen FPLC purified protein fractions to the 50 mL centrifugal filter (30 kDa cutoff) and centrifuge using the settings in Step A6b.Note: Single-chain biosensors that merge OpuBC, cpGFP, and two 4-residue linkers have a molecular weight of approximately 62 kDa. The 30 kDa cutoff is probably appropriate for concentrating all known biosensors that merge a PBP moiety with a fluorescent protein moiety. Repeat Step A6c until all desired fractions are added to the filter and centrifuged.Add 8 mL of 1√ó PBS, pH 7.0, to the centrifugal filter and centrifuge using the settings in Step A6b.",
    "Repeat Step A6e six more times to buffer exchange the biosensor solution and remove all residual imidazole.When the final centrifugation is reached, determine the volume of the biosensor in the centrifugal filter. If it is 500‚Äì1,000 ¬µL, continue to Step A6h. If it is >1,000 ŒºL, centrifuge the biosensor solution at 3,400 √ó g in 3 min increments until the volume is 500‚Äì1,000 ¬µL.Note: A volume of 500‚Äì1,000 ¬µL generally provides a protein concentration of 50‚Äì200 ŒºM. 250 ŒºL of biosensor protein at 50 ŒºM is generally sufficient to run several screens and perform the multiple concentration drug‚Äìbiosensor fluorescence validations. Measure the A280 of the protein on Nanodrop 1000 (or equivalent UV-Vis spectrophotometer) using the manufacturer‚Äôs instructions. After obtaining the A280, determine the concentration using Beer‚Äôs Law. The appropriate extinction coefficient for each biosensor being purified is calculated from the amino acid composition.Note: Purification of protein from 200 mL of autoinduction media generally provides a final yield of 0.2‚Äì2.0 mg. Aliquot the biosensor solution into 0.5 mL tubes and flash freeze in liquid nitrogen.CRITICAL STEP¬†Multiple freeze-thaw cycles are not recommended, so storage in 20‚Äì50 ¬µL aliquots is recommended. Store the biosensor solutions at -80 ¬∞C.TROUBLESHOOTING¬†If biosensor yield is low (less than 250 ŒºL at 50 ŒºM), the following suggestions are recommended: increase autoinduction time to the 30 h maximum, remake auto-induction solutions and repeat autoinduction, increase auto-induction volume, increase number of sonication rounds, and increase sonication amplitude. Although GFP-based biosensor protein production in E. coli is generally robust, some variability remains. Creation of drug plateAssembly of drug libraryChoose drugs based on criteria relevant to the project of interest (i.e., controlled substance scheduling, absence of existing biosensors, and clinical importance).",
    "Collect information on each drug and compile in Microsoft Excel for reference and comparison; this also allows tracking of delivery status and storage.Note: In our case, information was collected on each drug‚Äôs commercial availability, pharmacological or therapeutic class, trade name, rationale for study, IUPAC name, stereochemistry, chemical formula, formula weight, CAS number, formulation, structure, additional pharmacological properties, EC50, activity (agonist/antagonist), solubility, pKa, logP (octanol-water partition coefficient) or logDpH7.4 (logP corrected for fraction of uncharged (deprotonated) molecules at pH 7.4), controlled substance scheduling, handling instructions, vendor, price, and purity. Drug solvationChoose a solvation method for each drug based on solubility in water and organic solvents.CRITICAL STEP¬†If using PBP-based biosensors, avoid DMSO when possible (interactions between DMSO and PBP-based biosensors can result in high baseline fluorescence). Use 1√ó PBS (pH 7.0) as the solvent for water-soluble drugs.¬†TROUBLESHOOTING¬†It is suggested to perform small-scale tests of drug solubility in various solvent systems prior to drug plate formation to ensure complete dissolution. Water, 3√ó PBS (pH 7.0), ethanol, or methanol are recommended solvation systems. Calculate desired amount of drug to result in a drug solution at 2 mM, 2‚Äì8 mL.For drugs in powder form, use the following steps:Measure on a Mettler Toledo XPR204 scale and add the powder to a 15 mL Falcon tube.Add approximately 80% of the calculated appropriate solvent required by serological pipette and mix by vortexing.Measure the pH of the resulting solution and adjust to pH 7.0. CRITICAL STEP¬†The pH of a solution affects the baseline fluorescence of iDrugSnFRs (Shivange et al., 2019). This variation amounts to 10-fold per pH unit, or 26% per 0.1 pH unit. Consistency of pH across drug solutions will reduce variability in screen results. Add the remaining volume required to obtain a 2 mM concentration.",
    "Note: For solutions that do not dissolve fully by vortexing, place in a 42 ¬∞C heat bath until solvation is complete.¬†CRITICAL STEP¬†Ensure that the drug is completely dissolved before continuing to drug plate formation. For drugs in liquid form, use the following steps:Dilute drug directly into 80% of the calculated appropriate solvent.Mix drug by vortexing.Measure the pH of the resulting solution and adjust to pH 7.0. CRITICAL STEP¬†The pH of a solution affects the baseline fluorescence of iDrugSnFRs (Shivange et al., 2019). This variation amounts to 10-fold per pH unit, or 26% per 0.1 pH unit. Consistency of pH across drug solutions will reduce variability. Add the remaining volume required to obtain a 2 mM concentration.CRITICAL STEP¬†Ensure that the drug is completely dissolved before continuing to drug plate formation. Drug plate formatting and compilationDesign a 2.2 mL (deep-well) 96-well drug plate with drugs of interest (Figure 2).Add three control wells for each solvation condition and intersperse these across the plate to monitor potential cross contamination due to pipetting.Add 1 mL of the appropriate drug solution or solvent to each well.Store the remaining drug solution as described in MSDS for future screening plates.imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g002.jpgFigure 2. Drug plate design example of a drug‚Äìbiosensor fluorescence screen. The drug plate design used for a single concentration drug‚Äìbiosensor fluorescence screen is shown, with drugs organized by class and control wells mixed throughout the plate.Single concentration drug‚Äìbiosensor fluorescence screenBiosensor dilutionThaw a biosensor protein aliquot on ice.Dilute the biosensor in 3√ó PBS, pH 7.0, so that the diluted solution has a concentration of 111 nM and volume of 30‚Äì50 mL.Transfer the solution to a 50 mL Falcon tube and mix by inversion.Mixing of drug‚Äìbiosensor solution using epMotion liquid handling robotCreate a program in the Eppendorf ePBlue software for biosensor screening.",
    "Note: This program needs a location for a 50 ¬µL Eppendorf pipette tip box (for distributing drug solution), 300 ¬µL Eppendorf pipette tip box (for distributing biosensor solution), the 2.2 mL 96-well drug plate containing 1 mL drug solutions created in Step B3, three 360 ¬µL 96-well plates (for mixed drug‚Äìbiosensor solution), and a 50 mL tube containing biosensor solution (Figure 3). The program must allow for 100 ¬µL biosensor solution to be added from the 50 mL tube to each well of the three 360 ¬µL 96-well plates (using 300 ¬µL tips), 11 ¬µL of drug solution to be added from the 2.2 mL 96-well drug plate containing 1 mL drug solution to corresponding wells of the three 360 ¬µL 96-well plates (using 50 ¬µL tips), and a step for the mixing of drug and biosensor solutions. The data from drug-containing wells on these plates will serve as the Drug‚ÄìBiosensor Fluorescence values for ŒîF/F0 calculations in Equation 1 (Data analysis). The data from the solvent control wells from this plate (i.e., 25% DMSO, 3√ó PBS, pH 7.0) will serve as Baseline Biosensor Fluorescence for ŒîF/F0 calculations in Equation 1 (Data analysis). Run the program outlined in Step C2a.Note: This step can also be performed manually if a liquid handling robot is not available. Run the program outlined in Steps C2a-b with no biosensor present (i.e., 3√ó PBS, pH 7.0 only).Note: The data from these plates will serve as Baseline Drug Fluorescence for ŒîF/F0 calculations in Equation 1 (Data analysis). imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g003.jpgFigure 3. Eppendorf epMotion setup for single concentration drug‚Äìbiosensor fluorescence screen. The setup to mix drug and biosensor solutions is shown on the ePMotion 5075 liquid handling robot. This shows a 2.",
    "2 mL 96-well plate with 1 mL of drug/solvent solutions in position B1, p50 tips in B2, p300 tips in B3, 360 ¬µL 96-well plates in C2‚ÄìC4, and containers of biosensor solution (2√ó 50 mL tubes) in C5, as desired.Fluorescence measurements using Spark 10MRemove 360 ¬µL 96-well plates one at a time from the Eppendorf machine and place into the plate holder of the Spark 10M Fluorescence Reader.Design a program to measure fluorescence of the drug‚Äìbiosensor solution. Our program contains the following elements: it shakes the plate for 10 s at an amplitude of 1.5 mm to allow for additional mixing and then measures fluorescence with an excitation wavelength of 480 nm and emission wavelength of 535 nm.Note: An excitation wavelength of 480 nm and emission wavelength of 535 nm is appropriate for all GFP-based biosensors. If a different fluorescent protein is being used, the excitation and emission wavelengths should be adjusted to match its fluorophore. Example results:  2017 single concentration drug‚Äìbiosensor fluorescence screen In 2017, a single concentration drug‚Äìbiosensor fluorescence screen was conducted with a primary focus on drugs used to treat psychiatric disorders (Figure 4). Drugs were chosen both based on clinical importance and to encompass a range of pharmacological or therapeutic classes; classes present included opioids, anticholinergics, antipsychotics, antidepressants, benzodiazepines, anti-seizure medications, and sedatives. In total, 84 drugs and 13 biosensors were screened. We also grouped results into general categories based on the most common treatment use: schizophrenia, major depressive disorder, anxiety disorders, epilepsy, and other.¬† ¬†As noted, a hit pair comprises a pair of molecules: drug and biosensor. In total, 190 drug‚Äìbiosensor hit pairs were identified, with ŒîF/F0 ranging from 1.0 to 18.5.",
    "From these, 108 hit pairs had 1 < ŒîF/F0 < 3 and thus could likely be used to generate optimized biosensor variants through directed evolution. The remaining 82 hits had ŒîF/F0 > 3 and thus could likely be used for cellular imaging without further mutations. Hit pairs were concentrated in three clinical use categories (schizophrenia, major depressive disorder, and other), with no hit pairs identified for anxiety and epilepsy drugs. The v7.1.2 biosensor participated in the largest number of hit pairs; these also had the highest ŒîF/F0 values (Figure 4).imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g004.jpgFigure 4. Results map from the 2017 single concentration drug‚Äìbiosensor fluorescence screen. Fluorescence response (as represented by ŒîF/F0) for drug‚Äìbiosensor pairs included in the 2017 screen. Fluorescent response shading from green (ŒîF/F0 ‚â• 3) to white (ŒîF/F0 ‚â§ 0), in which stronger hits are represented by darker green, weaker hits by lighter green, and non-hits by white. Drug‚Äìbiosensor pairs that were not screened are in black.This screen allowed for the identification of drug‚Äìbiosensor pairs, from which the biosensor could potentially be evolved for engineering of novel variant biosensors for various neuropsychiatric medications. Biosensors for two nicotinic agonists, cytisine and dianicline, were engineered based on hit pairs obtained from this screen. The directed evolution of these sensors, as well as associated experiments on the subcellular pharmacokinetics of these drugs, are detailed in Nichols et al. (2022). The hit pair involving methadone became the basis for a selective variant, iS-methadoneSnFR (Muthusamy et al., 2022).¬† ¬†Because many of the drugs included in this screen are sparingly water-soluble, DMSO was often used for dissolution. However, this screen showed that DMSO interacts with several biosensor candidates, even in the absence of a DOI.",
    "This phenomenon resulted in the presence of many negative ŒîF/F0s, as the baseline biosensor fluorescence was higher than would be reasonable if the biosensor and solvent were not interacting. This showed that additional normalizations and corrections would be required when DMSO was used as a solvent with iDrugSnFRs (see Notes). We have not systematically studied the residues responsible for DMSO sensitivity.¬† ¬†The 2017 screen was also informative in showing a failure: we found no hit pairs involving S-ketamine, its enantiomers, or its metabolites. Faute de mieux, we performed site-saturated mutagenesis on a residue, Tyr357, that makes a key cation-œÄ interaction with nicotinic drugs (Shivange et al., 2019; Unger et al., 2020). This resulted in the S-ketamine responsive Tyr357Gly construct termed AK1, and we evolved AK1 into variants that satisfactorily sense S-ketamine. We included these variants in subsequent screens described below.2018 single concentration drug‚Äìbiosensor fluorescence screen The 2018 screen was conducted to identify biosensor‚Äìdrug hit pairs for opioids of several categories (Figure 5). Drugs included in the screen were chosen based on clinical importance, as well as presence in the existing literature. Most opioids included activate the Œº opioid receptor, though several drugs target Œ∫ and ùõø opioid receptors. An Other category was composed of opioid inhibitors. In total, 48 drugs and 16 biosensors were included. From these pairs, 205 total drug‚Äìbiosensor hits were identified. Of these, 128 hits had 1 < ŒîF/F0 < 3, while 76 had ŒîF/F0 > 3. Thirty of the 48 drugs tested participated in at least one hit pair, with most having hit pairs with several biosensors (one drug had a single hit pair). Additionally, each biosensor participated in a hit pair with at least one drug. The proportion of hit pairs varied by drug category.",
    "No hit pairs were found for ¬µ opioids ligands, while the largest proportion of hit pairs were found for ¬µ opioid ligands. Hit pairs also varied in fluorescence response, with the weakest pair having a ŒîF/F0 of 1.0 (our at least definition for a hit pair) and the strongest pair having a ŒîF/F0 of 19.0 (tapentadol √ó biosensor v7). Generally, the v7 biosensor series (including v7, v7.1, v7.1.2, v8, and v9) had strong responses with Œº opioids (Figure 5).¬† ¬†This screen allowed for the identification of drug‚Äìbiosensor pairs that could lead to the engineering of novel opioid biosensor variants. Furthermore, this screen showed many strong hit pairs involving clinically relevant Œº opioid ligands, which could allow for direct cellular imaging or efficient generation of novel biosensors for this drug class.imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g005.jpgFigure 5. Results map from the 2018 single concentration drug‚Äìbiosensor fluorescence screen. Fluorescence response (as represented by ŒîF/F0) for drug‚Äìbiosensor pairs included in the 2018 single concentration drug‚Äìbiosensor fluorescence screen. Drugs are grouped by opioid category. Fluorescent response shading from green (ŒîF/F0 ‚â• 3) to white (ŒîF/F0 = 0), in which stronger hits are represented by darker green, weaker hits by lighter green, and non-hits by white.2019 single concentration drug‚Äìbiosensor fluorescence screen The 2019 screen was completed to identify hit pairs involving previously unscreened classes of CNS-acting drugs (Figure 6). Several drugs were included from each of five classes: 5-HT3 antagonists, anticholinergics, CB1/CB2 ligands, opioids, and neonicotinoids. Individual drugs of interest from a range of classes were also included and designated by an Other category. In total, 44 drugs were included and tested against 18 biosensor proteins. A total of 106 drug‚Äìbiosensor hit pairs were identified, with 81 having 1 < ŒîF/F0 < 3 and 24 having ŒîF/F0 > 3.",
    "Twenty-one of the 44 drugs chosen participated in a hit pair with at least one biosensor. Additionally, each biosensor had a hit pair with at least one drug. Certain biosensors showed strong responses with several drugs in the same class. For example, L194D1 [a precursor to the biosensor iSeroSnFR, which detects serotonin (Unger et al., 2020)] displayed hit pairs for six CB1/CB2 ligands, with responses ranging from ŒîF/F0 of 3.5‚Äì5.0. Several other biosensors (v4.6, v.4.8.1.2, v7 436A, and Scop4) also participated in hit pairs with several CB1/CB2 ligands, albeit less strongly (Figure 6).¬† ¬†This screen expanded the number of drug‚Äìbiosensor hit pairs identified that could be used for engineering of novel variants, as well as the range of drug classes. 5-HT3 antagonists participated in many hit pairs and also showed promising results in validation through dose-response measurements (below).imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g006.jpgFigure 6. Results map from the 2019 single concentration drug‚Äìbiosensor fluorescence screen results map. Fluorescence response (as represented by ŒîF/F0) for drug‚Äìbiosensor pairs included in the 2019 single concentration drug‚Äìbiosensor fluorescence screen. Drugs are grouped by class. Fluorescent response shading from green (ŒîF/F0 ‚â• 3) to white (ŒîF/F0 = 0), in which stronger hits are represented by darker green, weaker hits by lighter green, and non-hits by white.Drug‚Äìbiosensor fluorescence validation of hit pairs through multiple concentration response experimentsCreation of drug dilution plateChoose a drug-biosensor hit pair for a multiple concentration response experiment.Create a drug dilution plate that allows for a triplicate dose-response relation measurement of the desired drug. CRITICAL STEP¬†Accurate drug concentrations in the drug dilution plate are necessary for accurate calculations of the drug‚Äìbiosensor interaction. Pipette 1 mL of 2 mM drug solution into wells A1‚ÄìC1 of a 2.2 mL 96-well plate.Perform a ‚àö1 0¬† dilution eight times.Transfer 316 ¬µL of solution from A1‚ÄìC1 wells to A2‚ÄìC2.",
    "Add 684 ¬µL of 3√ó PBS, pH 7.0, to wells A2‚ÄìC2 and mix by pipette.Transfer 316 ¬µL of solution from wells A2‚ÄìC2 to wells A3‚ÄìC3, add 684 ¬µL of 3√ó PBS, pH 7.0, and mix.Repeat above steps until wells A9‚ÄìC9 are filled.Add 684 ¬µL of 3√ó PBS, pH 7.0, to wells A10‚ÄìC10 to serve as a blank.Biosensor dilutionThaw a biosensor protein aliquot from Step A6j on ice.Dilute the biosensor in 3√ó PBS, pH 7.0, so that the diluted solution has a concentration of 111 nM and volume of 30‚Äì50 mL.Transfer the solution to a 50 mL Falcon tube and mix by inversion.Mixing of drug‚Äìbiosensor solution using epMotion liquid handling robotCreate a program in the Eppendorf ePBlue software for validating biosensor hit pairs.Note: This program needs a location for a 50 ¬µL Eppendorf pipette tip box (for distributing drug solution), 300 ¬µL Eppendorf pipette tip box (for distributing biosensor solution), the 2.2 mL 96-well drug plate containing 1 mL drug solutions created in Step D1, one 360 ¬µL 96-well plate (for mixed drug‚Äìbiosensor solution), and a 50 mL Falcon tube containing biosensor solution. The program must allow for 11 ¬µL of drug solution to be added from the 2.2 mL 96-well drug plate containing 1 mL drug solutions to corresponding wells of the 360 ¬µL 96-well plate, 100 ¬µL of biosensor solution to be added from the 50 mL Falcon tube to the same wells of the 360 ¬µL 96-well plate, and for these solutions to be mixed (there will only be drug and biosensor solution in wells A‚ÄìC 1‚Äì9 of the plate if the 2.2 mL 96-well drug plate containing 1 mL drug solutions is set up as instructed in step D1).",
    "The data from columns 1‚Äì9 will serve as the Drug‚ÄìBiosensor Fluorescence values for ŒîF/F0 calculations in Equation 1 (Data analysis). The data from column 10 will serve as Baseline Biosensor Fluorescence for ŒîF/F0 calculations in Equation 1 (Data analysis). Run the program outlined in Step C2a.Notes:  This step can also be performed manually if a liquid handling robot is not available. The range of drug concentration sampled can be increased or decreased as needed to sample a full dose-response relation. Fluorescence measurements using Spark 10MOnce the program on the epMotion liquid handling robot is complete, remove the 360 ¬µL 96-well plate from the Eppendorf machine and place it into the plate holder of the Tecan Spark 10M Fluorescence Reader.Utilize the same program as in step C3b.Repeat steps D3‚Äì4 with no biosensor present (i.e., 3√ó PBS, pH 7.0 only)Note: The data from these plates will serve as Baseline Drug Fluorescence for ŒîF/F0 calculations in Equation 1 (Data analysis). Example results for future studies:  5-HT3 receptor Antagonists Four 5-HT3 antagonists were included in the 2019 screen: ondansetron, tropisetron, palonosetron, and alosetron. In this class, 23 hit pairs involved drugs, including several pairs found for ondansetron, tropisetron, and palonosetron. No hit pairs were found for alosetron. Top hit pairs for each drug were validated through multiple concentration drug‚Äìbiosensor fluorescence dose-response studies as described in step D above (Figure 7).¬† ¬†Additionally, these validations allowed for the calculation of EC50, Hill coefficient (nH, a measure of apparent cooperativity among binding sites), and S-slope (as defined in Data analysis) of the drug‚Äìbiosensor hit pairs. Validation screens were conducted for the four strongest hit pairs for each DOI. Thus, ondansetron was studied against the biosensors AK1, cc70, v7.1.2, and Scop4; tropisetron was studied against the biosensors AK1, v7.1, v7.1.",
    "2, and v8; and palonosetron was studied against the biosensors AK1, v7.1, v7.1.2, and Scop4. From these validation screens, the drug‚Äìbiosensor pairs with the most favorable profile were chosen (Figure 7). This was determined based on the S-slope, EC50, and Fmax of the drug‚Äìbiosensor pairs, with a higher Fmax, higher S-slope, and lower EC50 being most desirable.¬† Several 5-HT3 antagonist √ó biosensor hit pairs were validated through these dose-response relations. Two strong hit pairs were validated for palonosetron. Palonosetron √ó v7.1.2 displayed an Fmax of 5.4, and palonosetron √ó v7.1 displayed an Fmax of 3.2. We expect that both hit pairs have Fmax values large enough (i.e., > 3) to be used directly for cellular imaging. For ondansetron and tropisetron, a single hit pair was identified, with an Fmax of 2 for ondansetron √ó cc70 and an Fmax of 2.2 for tropisetron √ó v7.1.2. Because the Fmax values for these pairs are < 3, further directed evolution will be required to optimize a variant for successful use for imaging. For all hit pairs shown, nH is near 1, suggesting that the biosensors would have desired binding properties with these drugs.imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g007.jpgFigure 7. Multiple concentration drug‚Äìbiosensor fluorescence validations for 5HT3 antagonists. Dose-response relations (A) and analysis [Fmax, EC50, Hill coefficient (nH), and S-slope] (B) for 5-HT3 antagonists. Only the most promising dose-response relation(s) for each drug of interest are shown. Biosensors included are cc70, v7.1.2, and v7.1.CB1/CB2 Ligands The 2019 screen included nine CB1/CB2 ligands: SLV-319 (+/-), AM 6545, PSNCBAM-1, O-2050, WIN-55 212,22, CP 94545, NIDA 41020, rimonabant, and leelamine. In total, 34 hit pairs were found for drugs in this class, with several hit pairs being found for each of six drugs [SLV-319 (+/-), AM 6545, PSNCBAM-1, WIN-55 212,22, NIDA 41020, and rimonabant].",
    "We found no hit pairs including the remaining three drugs (O-2050, CP 94545, and leelamine).¬† ¬†The top four hit pairs for each drug were validated through multiple concentration drug‚Äìbiosensor fluorescence dose-response measurements. Thus, SLV-319 (+/-) was measured against the biosensors v4.6, v7A, and L194D1; AM 6545, rimonabant, and PSNCBAM-1 were measured against the biosensors AK1, v4.6, v7A, and L194D1; WIN-55 212,22 was measured against the biosensors v4.6, v4.8.1.2, v7A, and L194D1; and NIDA 41020 was measured against the biosensors v4.6, v4.8.1.2, Scop4, and L194D1.¬† ¬†From these screens, the drug‚Äìbiosensor pairs with the most favorable profile were chosen (Figure 8). This was determined based on the S-slope, EC50, and Fmax of the drug‚Äìbiosensor pairs, with a higher Fmax, higher S-slope, and lower EC50 being most desirable. The multiple concentration drug‚Äìbiosensor validations showed promising data for CB1/CB2 ligands: when calculated as S-slopes ((ŒîF/F0)/[Drug]) at 0.6 ¬µM, the sensitivities plotted in Figure 8 range from 1.6 to 6 ¬µM-1. Our limited supplies of the test drugs vitiated full dose-relations at saturated concentrations and Hill equation fits; but these data already suggest that it will be possible to conduct cellular experiments with these ligands at 1 < ¬µM. Further optimization may present the challenge of directed evolution in non-aqueous solvents such as DMSO or methanol.imgsrc:https://en-cdn.bio-protocol.org/attached/image/e4551/bioprotoc-12-22-4551-g008.jpgFigure 8. Multiple concentration drug‚Äìbiosensor fluorescence validations for CB1/CB2 ligands. Dose-response relations for CB1/CB2 ligands. Only the most promising dose-response relation(s) for each drug of interest are shown."
  ],
  "subjectAreas": [
    "Molecular Biology",
    "Neuroscience"
  ],
  "bigAreas": [
    "Biomedical & Clinical Research",
    "Molecular Biology & Genetics"
  ]
}